IVF Outcome Following Treatment With Ulipristal Acetate for Myomatous Uterus After at Least One IVF Failure
NCT ID: NCT02601196
Last Updated: 2016-07-12
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
PHASE4
Total Enrollment
20 participants
Study Classification
INTERVENTIONAL
Study Start Date
2016-09-30
Study Completion Date
2018-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Hypothesis:
After reviewing the relevant medical data the investigators assume that treating a woman with intramural fibroid not distorting the uterine cavity or mostly intramural with less than 50% submucosal component with Ulipristal Acetate (UPA) for a 13 weeks course would reduce the fibroid size and improve her chance for conceiving by IVF treatment.
Materials \& Methods:
Study design: A proof of concept prospective not randomized study. The patients: About 20 women treated in the fertility and IVF unit after at least one IVF failure, with mostly intramural (IM) fibroid \[class 2-5 by FIGO (International Federation of Gynecology and Obstetrics) classification system\] in the size of \>4 cm confirmed by Transvaginal ultrasound (TVUS) and diagnostic hysteroscopy.
After US examination and diagnostic hysteroscopy to ascertain suitability for this study, the investigators will offer a course of 13 weeks treatment with UPA 5 mg per day.
One month after cessation of treatment the investigators will perform another TVUS examination \& diagnostic hysteroscopy plus endometrial biopsy in order to assess the endometrial \& uterine status and will conduct an additional IVF cycle, using the same stimulation protocol undertaken during the immediate cycle previous to the UPA treatment course.
After reviewing the relevant medical data the investigators assume that treating a woman with intramural fibroid not distorting the uterine cavity or mostly intramural with less than 50% submucosal component with Ulipristal Acetate (UPA) for a 13 weeks course would reduce the fibroid size and improve her chance for conceiving by IVF treatment.
Materials \& Methods:
Study design: A proof of concept prospective not randomized study. The patients: About 20 women treated in the fertility and IVF unit after at least one IVF failure, with mostly intramural (IM) fibroid \[class 2-5 by FIGO (International Federation of Gynecology and Obstetrics) classification system\] in the size of \>4 cm confirmed by Transvaginal ultrasound (TVUS) and diagnostic hysteroscopy.
After US examination and diagnostic hysteroscopy to ascertain suitability for this study, the investigators will offer a course of 13 weeks treatment with UPA 5 mg per day.
One month after cessation of treatment the investigators will perform another TVUS examination \& diagnostic hysteroscopy plus endometrial biopsy in order to assess the endometrial \& uterine status and will conduct an additional IVF cycle, using the same stimulation protocol undertaken during the immediate cycle previous to the UPA treatment course.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Esmya Versus Surgery Before IVF/ICSI
NCT04028986
Fibroid; Uterus Tumor, Complicating Pregnancy
Infertility, Female
Surgical Procedure, Unspecified
ACTIVE_NOT_RECRUITING
Pregnancy Outcomes in Infertile Patients After Treatment With Ulipristal Acetate.
NCT03533907
Myoma;Uterus
Infertility, Female
COMPLETED
Ulipristal Acetate 10 mg and Asisted Reproduction
NCT02425878
Intramural Fibroids
Uterine Fibroids
TERMINATED
PHASE3
A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas
NCT02147197
Leiomyoma
Uterine Hemorrhage
COMPLETED
PHASE3
A Study of the Efficacy and Safety of Ulipristal Acetate Intermittent Treatment for Abnormal Uterine Bleeding Associated With Leiomyomas
NCT02147158
Leiomyoma
Uterine Hemorrhage
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Ulipristal Acetate - Study design
Introduction:
Leiomyomas are well established factors to affect fertility. The key factor for fertility disturbance is the fibroid location and not its size. The presence of submucosal fibroids has long been known to reduce fertility as opposed to subserosal fibroids which do not alter fertility. The effect of intramural fibroids on fertility is still a mystery.
These findings were best described in a meta-analysis of 23 studies:
* With no respect to location, women with fibroids have a lower chance for ongoing pregnancy or live birth (RR 0.7, 95% CI 0.59-0.83) and a greater chance for spontaneous abortion (RR 1.68, 95% CI 1.37-2.05).
* Women with fibroids that were submucosal or intramural with an intracavitary component were less likely to become pregnant (RR 0.36, 95% CI 0.18-0.74) and more likely to have a spontaneous abortion (RR 1.7, 95% CI 1.4-2.1).
* The picture is less clear for women with intramural fibroids. Overall, studies of women with fibroids that did not distort the uterine cavity were less likely to become pregnant (RR 0.81, 95% CI 0.70-0.94), less likely to have an ongoing pregnancy or to deliver a live newborn (RR 0.7, 95% CI 0.58-0.85) and more likely to have a spontaneous abortion (RR 1.7, 95% CI 1.2-2.5).
* In addition to these findings, women with cavity-distorting fibroids who undergone myomectomy had a significant increase in conception rate (RR 2.03, 95% CI 1.08-3.83).
* There were no significant differences between women who had myomectomy for intramural fibroids and those who did not go through surgical treatment, although the data for this issue is quite lame.
Another strong evidence for the relevance of intramural fibroids for fertility can be found in a meta-analysis that evaluated the association between non-cavity-distorting intramural fibroids and IVF outcome, this study shows a significant decrease in the live birth (RR 0.79, 95% CI 0.70 -0.88) and clinical pregnancy rate (RR 0.85, 95% CI 0.77 - 0.94) in women with non-cavity-distorting intramural fibroids compared with those without fibroids, following IVF treatment.
Ulipristal:
Ulipristal acetate (UPA) is a selective progesterone receptor modulator (SPRM) prescribed for women with symptomatic leiomyomas. Few phase 3 studies were conducted in order to prove its clinical use and efficacy in treating women suffering from fibroids.
* PEARL (PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomas) I was a randomized, double-blind, placebo controlled trial (48 patients in the placebo arm, 95 treated with daily dosage of 5 mg \& 94 with 10 mg of UPA) proving that treatment with UPA 5 mg or 10 mg once daily for a 13 weeks course is efficient in controlling uterine bleeding (91% \& 92% respectively) in comparison to placebo (19%), P\<0.001 for each dose. The rates of amenorrhea were 73%, 82% and 6% respectively. The median change in total fibroid volume was -22%, -12% \& +3% (p=0.002 for the 5 mg group \& 0.006 for the 10 mg group in comparison to the placebo group).
* PEARL II was a double blind non-inferiority trial comparing UPA (5 mg or 10 mg once daily) treatment for 3 months to once-monthly IM Leuprolide acetate 3.75 mg (97 patients in the 5 mg arm, 103 in the 10 mg arm \& 101 treated by Leuprolide acetate). The rates of uterine bleeding were comparable between the three groups - 90%, 98%, 89%. Median times to amenorrhea were 7 days, 5 days, 21 days - respectively. Adverse effects in the matter of moderate to severe hot flashes were much more common for women treated with Leuprolide acetate - 40% in comparison to those treated with UPA (11% for the 5 mg group \& 10% for the 10 mg group, p\<0.001 for both groups).
In November 2014 Luyckx et al. published a retrospective analysis of a series of 52 patients from one medical center (participants in PEARL II or PEARL III) - of these patients, 21 wished to conceive upon treatment completion - 15 of them (71%) succeeded for a total of 18 pregnancies.
* Median time to conceive was 10 months after completion of therapy.
* Two women who did not need myomectomy after completion of the UPA treatment achieved 3 of the pregnancies.
* 15 pregnancies were after myomectomy (8 by laparoscopy, 7 by laparotomy).
* 6 of the pregnancies (6 of 18, 33%) resulted in early missed abortion while 12 of the pregnancies ended in the live births of 13 babies. The relative high ratio of miscarriage can be related to the age of the women (median 36.4 years) and to high proportion of IVF (3/6 miscarriages).
* Only one of the deliveries was a vaginal delivery, 7 had elective cesarean delivery and 4 had emergent cesarean section.
* There was no significant fibroid regrowth during pregnancy.
* There was only one fetal anomaly in this cohort - in a patient who was treated by a new UPA course while she was already pregnant (unexpectedly) - a fetus showing ectopic right kidney on the inferior pole of the left kidney. A review of pregnancies after exposure to mifepristone to induce abortion or UPA given as emergency contraception shows no additional risk for congenital anomalies.
Selective progesterone receptor modulators as UPA are well known to induce endometrial modification known as PAEC (Progesterone receptor modulators Associated Endometrial Changes) - these changes are benign, non-proliferative \& non-physiological. This histological pattern is apparent in a large proportion of women after 13 weeks UPA treatment course (in PEARL I - 74.2% of the patients in the 5 mg group \& 70.4% in the 10 mg group; in PEARL II 65.1% in the 5 mg group \& 69.8% among the treated with 10 mg UPA). Endometrial biopsies taken six months after treatment cessation showed return to normal histological endometrial appearance. In both RCT's all endometrial biopsy examinations taken after week 13 showed only benign changes except: (a) one patient after 5 mg UPA treatment whose specimen showed simple hyperplasia and (b) one patient in the placebo group with complex atypical hyperplasia.
Hypothesis:
After reviewing the relevant medical data the investigators assume that treating a woman with intramural fibroid not distorting the uterine cavity or mostly intramural with less than 50% submucosal component with UPA for a 13 weeks course would reduce the fibroid size and improve her chance for conceiving by IVF treatment.
Materials \& Methods:
Study design: A proof of concept prospective not randomized study. The patients: About 20 women treated in our fertility and IVF unit after at least one IVF failure, with mostly intramural fibroid \[class 2-5 by FIGO classification system\] in the size of \>4 cm confirmed by TVUS and diagnostic hysteroscopy.
After US examination and diagnostic hysteroscopy to ascertain suitability for our study, we will offer a course of 13 weeks treatment with UPA 5 mg per day.
One month after cessation of treatment the investigators will perform another TVUS examination \& diagnostic hysteroscopy plus endometrial biopsy in order to assess the endometrial \& uterine status and will conduct an additional IVF cycle, using the same stimulation protocol undertaken during the immediate cycle previous to the UPA treatment course.
The data:
Demographic data - Age, BMI. Obstetrical data - Gravida, para. Gynecological data - Hormonal profile, uterus size, fibroids features (location, size), infertility features (duration, cause), past stimulation and IVF treatment variables.
Introduction:
Leiomyomas are well established factors to affect fertility. The key factor for fertility disturbance is the fibroid location and not its size. The presence of submucosal fibroids has long been known to reduce fertility as opposed to subserosal fibroids which do not alter fertility. The effect of intramural fibroids on fertility is still a mystery.
These findings were best described in a meta-analysis of 23 studies:
* With no respect to location, women with fibroids have a lower chance for ongoing pregnancy or live birth (RR 0.7, 95% CI 0.59-0.83) and a greater chance for spontaneous abortion (RR 1.68, 95% CI 1.37-2.05).
* Women with fibroids that were submucosal or intramural with an intracavitary component were less likely to become pregnant (RR 0.36, 95% CI 0.18-0.74) and more likely to have a spontaneous abortion (RR 1.7, 95% CI 1.4-2.1).
* The picture is less clear for women with intramural fibroids. Overall, studies of women with fibroids that did not distort the uterine cavity were less likely to become pregnant (RR 0.81, 95% CI 0.70-0.94), less likely to have an ongoing pregnancy or to deliver a live newborn (RR 0.7, 95% CI 0.58-0.85) and more likely to have a spontaneous abortion (RR 1.7, 95% CI 1.2-2.5).
* In addition to these findings, women with cavity-distorting fibroids who undergone myomectomy had a significant increase in conception rate (RR 2.03, 95% CI 1.08-3.83).
* There were no significant differences between women who had myomectomy for intramural fibroids and those who did not go through surgical treatment, although the data for this issue is quite lame.
Another strong evidence for the relevance of intramural fibroids for fertility can be found in a meta-analysis that evaluated the association between non-cavity-distorting intramural fibroids and IVF outcome, this study shows a significant decrease in the live birth (RR 0.79, 95% CI 0.70 -0.88) and clinical pregnancy rate (RR 0.85, 95% CI 0.77 - 0.94) in women with non-cavity-distorting intramural fibroids compared with those without fibroids, following IVF treatment.
Ulipristal:
Ulipristal acetate (UPA) is a selective progesterone receptor modulator (SPRM) prescribed for women with symptomatic leiomyomas. Few phase 3 studies were conducted in order to prove its clinical use and efficacy in treating women suffering from fibroids.
* PEARL (PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomas) I was a randomized, double-blind, placebo controlled trial (48 patients in the placebo arm, 95 treated with daily dosage of 5 mg \& 94 with 10 mg of UPA) proving that treatment with UPA 5 mg or 10 mg once daily for a 13 weeks course is efficient in controlling uterine bleeding (91% \& 92% respectively) in comparison to placebo (19%), P\<0.001 for each dose. The rates of amenorrhea were 73%, 82% and 6% respectively. The median change in total fibroid volume was -22%, -12% \& +3% (p=0.002 for the 5 mg group \& 0.006 for the 10 mg group in comparison to the placebo group).
* PEARL II was a double blind non-inferiority trial comparing UPA (5 mg or 10 mg once daily) treatment for 3 months to once-monthly IM Leuprolide acetate 3.75 mg (97 patients in the 5 mg arm, 103 in the 10 mg arm \& 101 treated by Leuprolide acetate). The rates of uterine bleeding were comparable between the three groups - 90%, 98%, 89%. Median times to amenorrhea were 7 days, 5 days, 21 days - respectively. Adverse effects in the matter of moderate to severe hot flashes were much more common for women treated with Leuprolide acetate - 40% in comparison to those treated with UPA (11% for the 5 mg group \& 10% for the 10 mg group, p\<0.001 for both groups).
In November 2014 Luyckx et al. published a retrospective analysis of a series of 52 patients from one medical center (participants in PEARL II or PEARL III) - of these patients, 21 wished to conceive upon treatment completion - 15 of them (71%) succeeded for a total of 18 pregnancies.
* Median time to conceive was 10 months after completion of therapy.
* Two women who did not need myomectomy after completion of the UPA treatment achieved 3 of the pregnancies.
* 15 pregnancies were after myomectomy (8 by laparoscopy, 7 by laparotomy).
* 6 of the pregnancies (6 of 18, 33%) resulted in early missed abortion while 12 of the pregnancies ended in the live births of 13 babies. The relative high ratio of miscarriage can be related to the age of the women (median 36.4 years) and to high proportion of IVF (3/6 miscarriages).
* Only one of the deliveries was a vaginal delivery, 7 had elective cesarean delivery and 4 had emergent cesarean section.
* There was no significant fibroid regrowth during pregnancy.
* There was only one fetal anomaly in this cohort - in a patient who was treated by a new UPA course while she was already pregnant (unexpectedly) - a fetus showing ectopic right kidney on the inferior pole of the left kidney. A review of pregnancies after exposure to mifepristone to induce abortion or UPA given as emergency contraception shows no additional risk for congenital anomalies.
Selective progesterone receptor modulators as UPA are well known to induce endometrial modification known as PAEC (Progesterone receptor modulators Associated Endometrial Changes) - these changes are benign, non-proliferative \& non-physiological. This histological pattern is apparent in a large proportion of women after 13 weeks UPA treatment course (in PEARL I - 74.2% of the patients in the 5 mg group \& 70.4% in the 10 mg group; in PEARL II 65.1% in the 5 mg group \& 69.8% among the treated with 10 mg UPA). Endometrial biopsies taken six months after treatment cessation showed return to normal histological endometrial appearance. In both RCT's all endometrial biopsy examinations taken after week 13 showed only benign changes except: (a) one patient after 5 mg UPA treatment whose specimen showed simple hyperplasia and (b) one patient in the placebo group with complex atypical hyperplasia.
Hypothesis:
After reviewing the relevant medical data the investigators assume that treating a woman with intramural fibroid not distorting the uterine cavity or mostly intramural with less than 50% submucosal component with UPA for a 13 weeks course would reduce the fibroid size and improve her chance for conceiving by IVF treatment.
Materials \& Methods:
Study design: A proof of concept prospective not randomized study. The patients: About 20 women treated in our fertility and IVF unit after at least one IVF failure, with mostly intramural fibroid \[class 2-5 by FIGO classification system\] in the size of \>4 cm confirmed by TVUS and diagnostic hysteroscopy.
After US examination and diagnostic hysteroscopy to ascertain suitability for our study, we will offer a course of 13 weeks treatment with UPA 5 mg per day.
One month after cessation of treatment the investigators will perform another TVUS examination \& diagnostic hysteroscopy plus endometrial biopsy in order to assess the endometrial \& uterine status and will conduct an additional IVF cycle, using the same stimulation protocol undertaken during the immediate cycle previous to the UPA treatment course.
The data:
Demographic data - Age, BMI. Obstetrical data - Gravida, para. Gynecological data - Hormonal profile, uterus size, fibroids features (location, size), infertility features (duration, cause), past stimulation and IVF treatment variables.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Women With Leiomyoma After at Least One Unsuccessful IVF Treatment
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ulipristal acetate treatment
Women who receive UPA treatment before another IVF cycle.
Group Type
OTHER
Ulipristal acetate
Intervention Type
DRUG
Transvaginal US and diagnostic hysteroscopy - to ascertain suitability. A therapeutic course of ulipristal acetate 5 mg per day for 13 weeks. After completion of the treatment protocol - another TVUS, diagnostic hysteroscopy and histological examination of the endometrium - to assess results of UPA treatment.
Another IVF cycle.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ulipristal acetate
Transvaginal US and diagnostic hysteroscopy - to ascertain suitability. A therapeutic course of ulipristal acetate 5 mg per day for 13 weeks. After completion of the treatment protocol - another TVUS, diagnostic hysteroscopy and histological examination of the endometrium - to assess results of UPA treatment.
Another IVF cycle.
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Infertile women in the age of 18-44 years
* At least after one failure in IVF treatment
* Normal responders (more than 3 oocytes retrieved in previous controlled ovarian hyperstimulation treatment).
* Intramural fibroid between 4-10 cm, not distorting the uterine cavity
* At least after one failure in IVF treatment
* Normal responders (more than 3 oocytes retrieved in previous controlled ovarian hyperstimulation treatment).
* Intramural fibroid between 4-10 cm, not distorting the uterine cavity
Exclusion Criteria
* Intolerance for UPA treatment
* Fibroids distorting the uterine cavity
* Poor responder
* Fibroids distorting the uterine cavity
* Poor responder
Minimum Eligible Age
18 Years
Maximum Eligible Age
44 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sheba Medical Center
OTHER_GOV
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Eran Zilberberg
Doctor, IVF unit
Responsibility Role
PRINCIPAL_INVESTIGATOR
References
Explore related publications, articles, or registry entries linked to this study.
Klatsky PC, Tran ND, Caughey AB, Fujimoto VY. Fibroids and reproductive outcomes: a systematic literature review from conception to delivery. Am J Obstet Gynecol. 2008 Apr;198(4):357-66. doi: 10.1016/j.ajog.2007.12.039.
Reference Type
BACKGROUND
Pritts EA, Parker WH, Olive DL. Fibroids and infertility: an updated systematic review of the evidence. Fertil Steril. 2009 Apr;91(4):1215-23. doi: 10.1016/j.fertnstert.2008.01.051. Epub 2008 Mar 12.
Reference Type
BACKGROUND
Casini ML, Rossi F, Agostini R, Unfer V. Effects of the position of fibroids on fertility. Gynecol Endocrinol. 2006 Feb;22(2):106-9. doi: 10.1080/09513590600604673.
Reference Type
BACKGROUND
Sunkara SK, Khairy M, El-Toukhy T, Khalaf Y, Coomarasamy A. The effect of intramural fibroids without uterine cavity involvement on the outcome of IVF treatment: a systematic review and meta-analysis. Hum Reprod. 2010 Feb;25(2):418-29. doi: 10.1093/humrep/dep396. Epub 2009 Nov 12.
Reference Type
BACKGROUND
Donnez J, Tatarchuk TF, Bouchard P, Puscasiu L, Zakharenko NF, Ivanova T, Ugocsai G, Mara M, Jilla MP, Bestel E, Terrill P, Osterloh I, Loumaye E; PEARL I Study Group. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012 Feb 2;366(5):409-20. doi: 10.1056/NEJMoa1103182.
Reference Type
BACKGROUND
Donnez J, Tomaszewski J, Vazquez F, Bouchard P, Lemieszczuk B, Baro F, Nouri K, Selvaggi L, Sodowski K, Bestel E, Terrill P, Osterloh I, Loumaye E; PEARL II Study Group. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med. 2012 Feb 2;366(5):421-32. doi: 10.1056/NEJMoa1103180.
Reference Type
BACKGROUND
Luyckx M, Squifflet JL, Jadoul P, Votino R, Dolmans MM, Donnez J. First series of 18 pregnancies after ulipristal acetate treatment for uterine fibroids. Fertil Steril. 2014 Nov;102(5):1404-9. doi: 10.1016/j.fertnstert.2014.07.1253. Epub 2014 Sep 17.
Reference Type
BACKGROUND
Bernard N, Elefant E, Carlier P, Tebacher M, Barjhoux CE, Bos-Thompson MA, Amar E, Descotes J, Vial T. Continuation of pregnancy after first-trimester exposure to mifepristone: an observational prospective study. BJOG. 2013 Apr;120(5):568-74. doi: 10.1111/1471-0528.12147. Epub 2013 Jan 24.
Reference Type
BACKGROUND
Gemzell-Danielsson K, Rabe T, Cheng L. Emergency contraception. Gynecol Endocrinol. 2013 Mar;29 Suppl 1:1-14. doi: 10.3109/09513590.2013.774591.
Reference Type
BACKGROUND
Williams AR, Bergeron C, Barlow DH, Ferenczy A. Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. Int J Gynecol Pathol. 2012 Nov;31(6):556-69. doi: 10.1097/PGP.0b013e318251035b.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SHEBA-15-2101-EZ-CTIL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Adenomyosis and Ulipristal Acetate
NCT02587000
COMPLETED
PHASE2
Observation of Long-term Effects on Endometrium and Uterine Fibroids in Women With Ulipristal Acetate Therapy
NCT03972917
COMPLETED
Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914
NCT00290251
COMPLETED
PHASE2
Ulipristal Acetate for the Preoperative Management of Hypoechoic Cellular Leiomyomas
NCT02361905
UNKNOWN
PHASE4
Impact of Esmya on Fertility to Infertile Women With Fibroids Managed With Assisted Reproduction Techniques
NCT03349190
COMPLETED
Ulipristal Acetate Versus GnRH Analogue and Myometrial Preservation
NCT02357563
UNKNOWN
PHASE4
Impact of Ultra-long Versus Long Down-regulation Protocol on IVF/ICSI in Adenomyosis
NCT03940807
WITHDRAWN
PHASE3
The Effect of Ulipristal Acetate (UPA) on Women Ovarian Reserve
NCT02361892
UNKNOWN
PHASE4
Efficacy and Safety Study of Ulipristal Acetate in Females With Anemia Associated With Uterine Leiomyoma
NCT01553123
WITHDRAWN
PHASE3
Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis
NCT03325868
WITHDRAWN
PHASE4
The Impact of a Novel GnRH Antagonist With Add-back Therapy for Treatment of Uterine Fibroids and Endometriosis on Hemostasis Parameters
NCT07173127
RECRUITING
NA
Endometrial Injury in Women With Unexplained Infertility
NCT02628756
COMPLETED
NA
Effects of Simvastatin on Uterine Leiomyoma Size
NCT03400826
RECRUITING
PHASE2
Endometrial Injury for Assisted Reproduction
NCT01132144
TERMINATED
PHASE3
The Value of Myomectomy in Women With Intramural Myoma Before IVF.
NCT03904368
UNKNOWN
NA
Endometrial Biopsy Prior to IVF in Those Patients With Prior Implantation Failure
NCT01800513
UNKNOWN
NA
The Effect of Simvastatin on Uterine Leiomyoma Development and Growth in Infertile Women
NCT03134157
UNKNOWN
PHASE3
PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata
NCT01642472
COMPLETED
PHASE3
Ulipristal for Endometriosis-related Pelvic Pain
NCT02213081
COMPLETED
PHASE4
A Prospective Multicenter Non-interventional Study of Women Treated With ESMYA (Ulipristal Acetate) as Pre-operative Treatment of Moderate to Severe Symptoms of Uterine Fibroids
NCT01635452
UNKNOWN
Magnetic Resonance (MR) Guided Focused Ultrasound Surgery of Uterine Fibroids
NCT00131365
COMPLETED
NA
Fibroids and Infertility - a Study of the Significance of Removal of Fibroids With Regard to Endometrial Receptivity
NCT04426760
UNKNOWN
Fertility After Myomectomy Versus Uterine Artery Embolization for Symptomatic Uterine Fibroids
NCT02577055
COMPLETED
NA
The Impact of Myomectomy on IVF Outcomes
NCT05932082
NOT_YET_RECRUITING
NA
MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids: Software V4.2 Validation
NCT00295217
COMPLETED
PHASE3